Ember co-founder Jason Binder is officially a published co-author in the Journal of Neuro-Oncology.
Public source
Publisher name
Public post
My cofounder Jason Binder is officially a published co-author in the Journal of Neuro-Oncology!💥 It is surreal to see Ember showing up in scientific literature around t…
Company
Ember
An AI companion for families facing serious illness. Free, in six disease areas.
- Industry
- Technology, Information and Internet
- Location
- San Francisco, US
- Company size
- 2–10 employees
About Ember
Ember is building support for the human side of serious illness, especially in the moments between appointments. We focus on what doesn’t show up in charts or visits. The decisions, questions, and emotional and logistical weight that families carry every day. We’re building thoughtfully alongside caregivers, clinicians, and researchers to create something that meets people where they are.
See moreLatest activity
Latest activity from Ember
3 signals
Products & Services
Ember now runs in six disease areas including glioblastoma, pediatric brain tumors, breast, multiple myeloma, ovarian, and pancreatic.
Presence & Recognition
Ember founder Jason Binder contributed the caregiver perspective to a publication highlighting lived experience of patients and caregivers alongside cancer care science.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Ataraxis AI
Ataraxis AI launched Ataraxis ARC, a large prospective study evaluating how clinical AI helps build truly personalized treatment plans and impacts outcomes for real patients.
Research & Knowledge
OncoveryCare
OncoveryCare Medical Director Dr. Erin Macrae MD published a piece in Doximity Op-Med discussing survivorship as a survival intervention and the need for a dedicated clinical partner to deliver comprehensive cancer care interventions.
Research & Knowledge
AccessHope
AccessHope published a research paper by Shealynn Buck, MD and Abhishek Kumar outlining the construct needed to approach dynamic times in healthcare in the context of cancer.
Research & Knowledge
Keto-Mojo
Keto-Mojo published a research study titled Postoperative recurrence of pancreatic cancer controlled for 9 months solely by severe carbohydrate restriction: ketogenic diet in the Journal of Clinical Gastroenterology.
Research & Knowledge
Sus Clinicals, Inc.